This announcement clearly states an order for reopren once...

This announcement clearly states an order for reopren once registered.

Solagran Limited
Solagran Limited
ACN 002 592 396
Level 11
492 St Kilda Road
Melbourne 3004
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155
19 October, 2006
Company Announcement
Trials Convince Leading St Petersburg Psychiatric Hospital to use Ropren for
Treatment of Chronic Alcoholism
The Directors of Solagran Limited are pleased to announce the receipt of a preliminary report
from the Skvortsova-Stepanov Psychiatric Hospital in St Petersburg relating to a five month
trial in which Ropren was used to treat patients suffering from the combined effects of
chronic alcoholism, opiate drug addiction and associated conditions.
In the preliminary report, the hospital’s Head Physician, Dr Vladimir Agishev advised that as
a result of the trial outcomes the hospital has decided to incorporate Ropren into its clinical
practice as an effective multi-action drug.
The Skvortsova-Stepanov Hospital is one of the leading psychiatric hospitals in Russia. It is
the same hospital that conducted the successful Alzheimer’s trial with Ropren in 2005 (refer
ASX announcement of 20 September, 2005). That trial demonstrated the potential of Ropren
to re-establish lost cognitive function in patients suffering from Alzheimer’s type dementia –
rather than just slow the rate of cognitive decline like existing Alzheimer’s treatments. Once
again, researchers were surprised by the high level of efficacy and the multi-faceted activity
of Ropren.
In the preliminary report, Dr Agishev stated that:
As a result of this trial, we can report positive changes in relation to all of the tested symptoms and
parameters. In comparison with the control group, the improvement in condition of the patients took
place at a much earlier stage and was expressed to a greater degree. The patients also reported an
improvement in wellbeing, extra energy and working capacity, and would remind medical staff not to
forget to give them the “wonder drops”.
…. Overall, Ropren was impressive and we intend to use it in our future clinical practice for treatment
of exogenic psychoses arising from alcohol and drug abuse.
He also indicated that Ropren was well tolerated by patients, with no side-effects or allergic
reactions being registered.
The full trials report is expected shortly, and a summary of the findings will be released to the
market in due course.
Dr Agishev and his team requested Ropren be provided in capsule or ampule form for use in
clinical practice, rather than the dropper employed in the trial. A VegeSoft capsule format has
already been developed in Australia in conjunction with Cardinal Health, and is being used in
the Neurocognitive Effects trial currently nearing completion at Swinburne University. A
report from the Swinburne study is expected in the first week of November.
2
The Directors believe that from a commercial perspective, the decision to use Ropren as
contained in the preliminary report is significant. Over the past three years, Solagran has
pursued a comprehensive Ropren trials program with two principal objectives. The first was
to establish Ropren as a low side effect treatment for a number of different conditions – in
particular chronic liver disease, neurodegenerative disorders and immune system disorders.
The second objective was to register it as a new pharmaceutical substance on the basis of
its ability to treat one of these conditions – liver disease.
It is now clear that clinicians are keen to have access to this substance as soon as it is
approved by the Russian Ministry of Health – and not only for the treatment of liver disease.
The fact that the Skvortsova-Stepanov Hospital intends to incorporate Ropren into its clinical
practice to treat chronic alcoholism will, in the opinion of the Directors, both increase the size
of the market for Ropren in Russia, and accelerate its take up rate.
Peter Stedwell
Company Secretary
On behalf of the Board